We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline... Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others. Show more
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
NASDAQ false 0001205922 0001205922 2024-02-27 2024-02-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...
NASDAQ false 0001205922 0001205922 2024-02-21 2024-02-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...
NASDAQ false 0001205922 --12-31 0001205922 2024-02-14 2024-02-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ...
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative...
NASDAQ false 0001205922 0001205922 2024-02-08 2024-02-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 9) Under the Securities Exchange Act of 1934...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.68 | -8.36408364084 | 8.13 | 8.4 | 7.45 | 7796 | 7.62276424 | CS |
4 | -1.36 | -15.4370034052 | 8.81 | 9.34 | 7.45 | 10732 | 8.09767871 | CS |
12 | -2.07 | -21.743697479 | 9.52 | 13.02 | 7.284214 | 75454 | 9.91384957 | CS |
26 | -7.81 | -51.1795543906 | 15.26 | 28.56 | 7.161 | 368083 | 14.84147282 | CS |
52 | -74.051 | -90.8590078649 | 81.501 | 100.8 | 7.161 | 288065 | 31.17425776 | CS |
156 | -643.55 | -98.8556067588 | 651 | 688.8 | 7.161 | 337240 | 231.56803037 | CS |
260 | -1137.05 | -99.3490607252 | 1144.5 | 2568.3 | 7.161 | 573724 | 686.65317683 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions